| Literature DB >> 31737110 |
Po-Han Huang1,2, Ching-Chih Hu2,3, Cheng-Hung Chien2,3,4, Li-Wei Chen2,3,4, Rong-Nan Chien1,2,3,4, Yi-Shiuan Lin5, Mei Chao1,6,7, Chih-Lang Lin1,2,3,4, Chau-Ting Yeh1,2.
Abstract
Background: The Aldehyde dehydrogenase 2 (ALDH2) mutant genotypes contain an allele encoding defective ALDH2 with reduced efficacy of alcohol metabolism leading to accumulation of highly toxic and carcinogenic acetaldehyde. It can induce unpleasant "Asian flush syndrome" and associate with increased risk of cancers. However, to date, little is known about ALDH2 genotypes in relation to the postoperative prognosis of hepatocellular carcinoma (HCC).Entities:
Keywords: ALDH2 genotype; hepatocellular carcinoma (HCC); overall survival.
Year: 2019 PMID: 31737110 PMCID: PMC6843870 DOI: 10.7150/jca.33221
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Basic clinical data for HCC patients included.
| Clinical parameters | |
|---|---|
| ALDH2 genotype, “GG”, n (%) | 202 (48.2%) |
| Gender, male, n (%) | 324 (77.3%) |
| Age, years, mean ± SD | 56.0 ± 14.2 |
| Anti-HCV, positive, n (%) | 101 (24.1%) |
| HBsAg, positive, n (%) | 303 (72.3%) |
| Alcoholism, yes, n (%) | 111 (26.5%) |
| Cirrhosis, yes, n (%) | 238 (56.8%) |
| Ascites, yes, n (%) | 28 (6.7%) |
| Microvascular invasion, yes, n (%) | 135 (32.2%) |
| Macrovascular invasion, yes, n (%) | 43 (10.3%) |
| Histology grade | |
| 1, n (%) | 11 (2.6%) |
| 2, n (%) | 179 (42.7%) |
| 3, n (%), | 192 (45.8%) |
| > 3, n (%) | 37 (8.8%) |
| Capsule, yes, n (%) | 305 (72.8%) |
| Tumor number | |
| 1, n (%) | 227 (61.4%) |
| 2, n (%) | 94 (22.4%) |
| 3, n (%) | 47 (11.2%) |
| >3, n (%) | 21 (5.0%) |
| Tumor size, cm, mean ± SD | 5.8 ± 4.0 |
| Alpha-fetoprotein, ng/mL, median (range) | 25.0 (< 2 to 685353) |
| Albumin, g/L, mean ± SD | 4.0 ± 0.6 |
| Bilirubin, mg/dL, mean ± SD | 1.1 ± 1.4 |
| Prothrombin time, sec, mean ± SD | 12.1 ± 1.4 |
| Creatinine, mg/dL, mean ± SD | 1.1 ± 0.9 |
| AST, U/L, mean ± SD | 65.2 ± 85.4 |
| ALT, U/L, mean ± SD | 66.5 ± 84.2 |
Comparison of clinical parameters between HCC patients carrying ALDH2 “GG” and non-“GG” (“AA” + “GA”) genotype.
| Clinical parameters | ALDH2 genotype | ||
|---|---|---|---|
| “GG” (n = 202) | “GA” + “AA” (n = 217) | P | |
| Gender, male, n (%) | 155 (76.7%) | 169 (77.9%) | 0.779 |
| Age, years, mean ± SD | 54.6 ± 14.4 | 57.2 ± 13.9 | 0.060 |
| Anti-HCV, positive, n (%) | 51 (25.2%) | 50 (23.0%) | 0.598 |
| HBsAg, positive, n (%) | 148 (73.3%) | 155 (71.4%) | 0.674 |
| Alcoholism, yes, n (%) | 72 (35.6%) | 39 (18.0%) | |
| Cirrhosis, yes, n (%) | 115 (56.9%) | 123 (56.7%) | 0.959 |
| Ascites, yes, n (%) | 13 (6.4%) | 15 (6.9%) | 0.845 |
| Microvascular invasion, yes, n (%) | 56 (27.7%) | 79 (36.4%) | 0.057 |
| Macrovascular invasion, yes, n (%) | 43 (10.3%) | 24 (11.1%) | 0.577 |
| Histology grade, > 2, n (%) | 105 (52.0%) | 124 (57.1%) | 0.289 |
| Capsule, yes, n (%) | 148 (73.3%) | 157 (72.4%) | 0.833 |
| Tumor number, > 1, n (%) | 77 (38.1%) | 85 (39.2%) | 0.825 |
| Tumor size, cm, mean ± SD | 5.7 ± 4.0 | 5.8 ± 4.0 | 0.707 |
| Alpha-fetoprotein, ng/mL, median (range) | 25.0 (< 2 to 443209) | 33.0 (< 2 to 685353) | 0.490 |
| Albumin, g/L, mean ± SD | 4.0 ± 0.5 | 3.9 ± 0.6 | 0.134 |
| Bilirubin, mg/dL, mean ± SD | 1.1 ± 1.6 | 1.1 ± 1.3 | 0.792 |
| Prothrombin time, sec, mean ± SD | 12.1 ± 1.4 | 12.1 ± 1.3 | 0.764 |
| Creatinine, mg/dL, mean ± SD | 1.1 ± 1.1 | 1.1 ± 0.7 | 0.994 |
| AST, U/L, mean ± SD | 60.9 ± 70.0 | 69.1 ± 97.6 | 0.326 |
| ALT, U/L, mean ± SD | 59.2 ± 60.6 | 73.2 ± 101.1 | 0.089 |
Figure 1Kaplan-Meier analysis of postoperative outcomes in HCC patients carrying ALDH2 “GG” versus “non-GG” genotype. (A) Recurrent-free survival. (B) Metastasis-free survival. (C) Overall survival. Green line, “GG” genotype; Blue line, “non-GG” genotype.
Cox proportional hazard analysis for association between clinical factors and time-to-distant metastasis.
| Clinical parameters | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| ALDH2 genotype, “GG” = 1 | 1.598 (1.032 - 2.474) | 1.704 (1.091 - 2.661) | ||
| Gender, male =1 | 1.217 (0.713 - 2.075) | 0.471 | ||
| Age, per year increase | 0.991 (0.976 - 1.007) | 0.266 | ||
| Anti-HCV, positive = 1 | 0.630 (0.355 - 1.120) | 0.116 | ||
| HBsAg, positive = 1 | 1.011 (0.620 - 1.648) | 0.966 | ||
| Alcoholism, yes = 1 | 1.063 (0.657 - 1.721) | 0.803 | ||
| Cirrhosis, yes = 1 | 0.811 (0.527 - 1.249) | 0.342 | ||
| Ascites, yes = 1 | 0.606 (0.191 - 1.922) | 0.395 | ||
| Microvascular invasion, yes = 1 | 2.984 (1.938 - 4.595) | 2.449 (1.568 - 3.824) | ||
| Macrovascular invasion, yes = 1 | 2.806 (1.623 - 4.852) | 2.218 (1.256 - 3.916) | ||
| Histology grade, per grade increase | 1.237 (0.907 - 1.687) | 0.178 | ||
| Capsule, yes = 1 | 0.862 (0.539 - 1.378) | 0.536 | ||
| Tumor number, per number increase | 1.323 (1.094 - 1.601) | 1.138 (0.926 - 1.397) | 0.219 | |
| Tumor size, per cm increase | 1.114 (1.068 - 1.161) | 1.063 (1.011 - 1.118) | ||
| Alpha-fetoprotein, per 1000 ng/mL increase | 1.005 (1.002 - 1.007) | 1.004 (1.001 - 1.007) | ||
| Albumin, per g/L increase | 0.830 (0.557 - 1.237) | 0.361 | ||
| Bilirubin, per mg/dL increase | 0.841 (0.571 - 1.238) | 0.380 | ||
| Prothrombin time, per sec increase | 1.016 (0.870 - 1.187) | 0.839 | ||
| Creatinine, per mg/dL increase | 0.592 (0.273 - 1.284) | 0.184 | ||
| AST, per U/L increase | 1.003 (1.001 - 1.005) | 1.001 (0.998 - 1.005) | 0.420 | |
| ALT, per U/L increase | 0.999 (0.996 - 1.002) | 0.501 | ||
Cox proportional hazard analysis for association between clinical factors and overall survival.
| Clinical parameters | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| ALDH2 genotype, “GG” = 1 | 2.242 (1.252 - 4.015) | 2.751 (1.513 - 5.002) | ||
| Gender, male =1 | 0.952 (0.507 - 1.789) | 0.879 | ||
| Age, per year increase | 0.997 (0.978 - 1.017) | 0.774 | ||
| Anti-HCV, positive = 1 | 0.738 (0.370 - 1.474) | 0.390 | ||
| HBsAg, positive = 1 | 0.967 (0.522 - 1.790) | 0.914 | ||
| Alcoholism, yes = 1 | 1.310 (0.725 - 2.369) | 0.371 | ||
| Cirrhosis, yes = 1 | 0.927 (0.532 - 1.614) | 0.788 | ||
| Ascites, yes = 1 | 2.961 (1.391 - 6.302) | 2.560 (1.154 - 5.677) | ||
| Microvascular invasion, yes = 1 | 2.177 (1.253 - 3.784) | 2.125 (1.191 - 3.794) | ||
| Macrovascular invasion, yes = 1 | 2.449 (1.189 - 5.042) | 1.776 (0.831 - 3.797) | 0.138 | |
| Histology grade, per grade increase | 1.350 (0.913 - 1.996) | 0.133 | ||
| Capsule, yes = 1 | 0.717 (0.401 - 1.284) | 0.263 | ||
| Tumor number, per number increase | 1.292 (1.018 - 1.639) | 1.173 (0.904 - 1.521) | 0.229 | |
| Tumor size, per cm increase | 1.084 (1.024 - 1.148) | 1.016 (0.954 - 1.082) | 0.630 | |
| Alpha-fetoprotein, per 1000 ng/mL increase | 1.002 (0.998 - 1.005) | 0.333 | ||
| Albumin, per g/L increase | 0.528 (0.332 - 0.841) | 0.662 (0.390 - 1.122) | 0.125 | |
| Bilirubin, per mg/dL increase | 1.102 (0.973 - 1.249) | 0.126 | ||
| Prothrombin time, per sec increase | 1.024 (0.844 - 1.242) | 0.809 | ||
| Creatinine, per mg/dL increase | 0.937 (0.658 - 1.335) | 0.720 | ||
| AST, per U/L increase | 1.004 (1.002 - 1.006) | 1.004 (1.001 - 1.007) | ||
| ALT, per U/L increase | 1.001 (0.998 - 1.004) | 0.504 | ||
Figure 2Forest plot analysis for overall survival in relation to ALDH2 “GG” versus “non-GG” genotype in different clinical subgroups.
Figure 4Forest plot analysis for recurrence-free survival in relation to ALDH2 “GG” versus “non-GG” genotype in different clinical subgroups.
Figure 3Forest plot analysis for metastasis-free survival in relation to ALDH2 “GG” versus “non-GG” genotype in different clinical subgroups.